Avastin’s revenue trends
In 3Q17, Roche Holding’s (RHHBY) Avastin generated revenues of 1.6 million Swiss francs, which reflected a ~4% fall on a year-over-year (or YoY) basis and a ~7% fall on a quarter-over-quarter (or QoQ) basis. In 3Q17, in the US, European, and Japanese markets, Avastin generated revenues of 677 million Swiss francs, 438 million Swiss francs, and 204 million Swiss francs, respectively, which reflected a ~5% fall, an ~8% fall, and a ~5% growth, respectively, YoY.
From January 2017 through September 2017, Avastin generated revenues of 5 million Swiss francs, which reflected a ~2% fall YoY.
In October 2017, the FDA (U.S. Food & Drug Administration) accepted Roche’s supplemental Biologics License Application (or sBLA) for Avastin in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin alone therapy for the front-line treatment of advanced ovarian cancer.
Rituxan revenue trends
In 3Q17, Rituxan generated revenues of 1.8 million Swiss francs, which reflected an ~8% fall on a QoQ basis. In 3Q17, Rituxan’s YoY revenues remained flat. In 3Q17, in the US, European, and Japanese markets, Rituxan generated revenues of 997 million Swiss francs, 406 million Swiss francs, and 75 million Swiss francs, respectively, which is a ~9% growth, a ~16% fall, and a ~7% growth, respectively, on a YoY basis.
From January 2017 through September 2017, Rituxan generated revenues of 5.6 billion Swiss francs, which is 2% growth on a YoY basis.
Rituxan is used in the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (or CLL), rheumatoid arthritis, and granulomatosis with polyangiitis. Some other drugs for CLL include Roche and AbbVie’s Venclexta, Gilead Sciences’ (GILD) Zydelig, Teva Pharmaceutical’s (TEVA) Treanda, Novartis’s (NVS) Arzerra, and Johnson & Johnson’s Imbruvica. Roche makes up ~0.84% of the Vanguard FTSE Developed Markets ETF (VEA).